(NASDAQ: BCYC) Bicycle Therapeutics's forecast annual revenue growth rate of 37.33% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.38%, and while it is forecast to beat the US market's average forecast revenue growth rate of 9.68%.
Bicycle Therapeutics's revenue in 2025 is $25,722,000.On average, 6 Wall Street analysts forecast BCYC's revenue for 2025 to be $2,716,555,207, with the lowest BCYC revenue forecast at $1,106,678,025, and the highest BCYC revenue forecast at $3,807,581,841. On average, 6 Wall Street analysts forecast BCYC's revenue for 2026 to be $2,807,693,398, with the lowest BCYC revenue forecast at $554,031,552, and the highest BCYC revenue forecast at $4,568,682,686.
In 2027, BCYC is forecast to generate $5,025,827,970 in revenue, with the lowest revenue forecast at $2,216,126,208 and the highest revenue forecast at $9,174,762,501.